TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Eli Lilly & Co ( (LLY) ) has provided an update.
On November 18, 2025, Eli Lilly & Co announced the election of Dr. Carolyn R. Bertozzi to its Board of Directors, effective December 8, 2025. Dr. Bertozzi, a distinguished professor at Stanford University, will serve on the Science and Technology Committee and the Ethics and Compliance Committee, and her appointment underscores Eli Lilly’s commitment to scientific excellence and ethical governance.
The most recent analyst rating on (LLY) stock is a Buy with a $1182.00 price target. To see the full list of analyst forecasts on Eli Lilly & Co stock, see the LLY Stock Forecast page.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly & Co’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The company’s robust revenue growth, market share gains, and strategic pipeline advancements are key strengths. However, high leverage, declining cash flow metrics, and a premium valuation present potential risks.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
Eli Lilly & Co is a pharmaceutical company that focuses on the development and sale of innovative medicines, primarily in the fields of oncology, immunology, neuroscience, and endocrinology.
Average Trading Volume: 3,793,296
Technical Sentiment Signal: Buy
Current Market Cap: $992.3B
Find detailed analytics on LLY stock on TipRanks’ Stock Analysis page.